Letter sent to any patient that has an insurance plan that frequently pays the member.
Medicare Coverage Update
Date: 07/01/2020
Dear Client,
Last Name, First Name House number and street name City, State, Zip Code
Novitas Medicare revised their Limited Coverage Decision (LCD) for Qualitative and Quantitative Drug Testing, effective 10/01/2021. The full Controlled Substance Monitoring and Drugs of Abuse Testing Policy (A56645) can be found at: http://www.novitas-solutions.com/ & https://www.cms.gov/. Alternatively, DRUGSCAN can provide you with a copy of the Medicare LCD updated 10/01/2021. Should you have questions regarding this communication please contact the DRUGSCAN Billing Department at 844.345.1821. Please note that DRUGSCAN does not and cannot provide guidance or direction on our referring physicians’ internal billing or reimbursement practices. Only the physician can determine the specific diagnosis(es) code(s) that are applicable to a specific patient on a specific date of service, and DRUGSCAN must rely on the physician to provide the appropriate diagnosis(es) code(s). This diagnosis code reference guide is provided as an aid to physicians and office staff in determining when an ABN (Advance Beneficiary Notice) is necessary. Diagnosis codes must be applicable to the patient’s symptoms or conditions and must be consistent with documentation in the patient’s medical record. DRUGSCAN does not recommend any diagnosis codes and will only submit diagnosis information provided to us by the ordering physician or his/her designated staff. The CPT codes provided are based on AMA guidelines and are for informational purposes only. For informational and reference purposes only, attached are the most common ICD-10 codes submitted to DRUGSCAN.
Dear [Customer Name]
On 07/01/2020 your Physician requested laboratory testing performed by DRUGSCAN ® . We since submitted a claim to your insurance company, (“Name of Insurance”), for payment of this test. Because we are not directly contracted with this insurance company, they may send payment for this service directly to you. This is not because of anything your physician or DRUGSCAN ® failed to do. Instead, your insurance company pays you directly so you can pay out of network providers. We will continue to work with (“Name of Insurance”) to eliminate this confusing and inefficient practice of sending payments directly to patients like yourself (rather than to the provider, as most insurance companies do). We expect you may receive a check for several hundred dollars from your insurance company, along with an Explanation of Benefits (“EOB”) that describes certain lab testing performed on 05/01/2020. If you receive such a payment from your insurance company, please sign the check on the back and indicate “Pay to the order of DRUGSCAN ® , Inc.”. Please mail the check and any correspondence that accompanied the payment in the enclosed return envelope using the pre-addressed return page. In addition, you may have additional patient responsibility for any co- pay, co-insurance or deductible that your insurance EOB states. This may be billed back to you on a separate statement. If the information you receive from your insurance company does not include a payment, you do not need to do anything unless you receive a bill from DRUGSCAN ® , Inc. EOBs are not requests for payment, but information from your insurance company to you. We appreciate your assistance in this matter. If you have any questions or concerns please contact billing customer service at 1.844.345.1821 or at patient.billing @ DRUGSCAN.com.
Sincerely, DRUGSCAN ® , Inc.
Sincerely, Customer Service DRUGSCAN ® , Inc.
PO Box 347, Horsham, PA 19044 | 844.345.1821 | patient.billing @ DRUGSCAN.com
28
29
Made with FlippingBook Digital Proposal Creator